Sveriges mest populära poddar
Pharmaceutical Executive
VetenskapLife Science

Pharmaceutical Executive Daily: FDA Expands Approvals for Tzield and Dupixent

2 min•23 april 2026
In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixent receives an expanded pediatric indication in chronic spontaneous urticaria, and AbbVie announces a $195 million investment to build a new manufacturing campus in North Carolina.

Fler avsnitt av Pharmaceutical Executive

Visa alla avsnitt av Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Approves Datroway
•2 min
Pharmaceutical Executive Daily: What It Takes to Move Machine Learning
•3 min
Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio
•4 min
Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs
•3 min
Rethinking Pharma's Go-to-Market Formula
•21 min
Pharmaceutical Executive Daily: FDA Approves Baxdrostat
•2 min
Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra
•3 min
Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi
•4 min
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
•3 min
Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen
•3 min

Pharmaceutical Executive med Pharmaceutical Executive Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.